Update shared on 01 Nov 2025
Shilpa Medicare's analyst price target remains unchanged at ₹514.5, as analysts continue to reaffirm their estimates based on stable forecasts for the company’s growth and profitability metrics.
What's in the News
- Shilpa Medicare Limited will hold a Special/Extraordinary Shareholders Meeting via postal ballot on November 8, 2025 (company announcement).
- The company has secured the world's first regulatory approval from India's CDSCO for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, which is the first approved therapy targeting NAFLD. Shilpa Medicare plans to rapidly commercialize this product in India and pursue international approvals (company announcement).
- The company announced a 2:1 stock split or significant stock dividend, which will take effect on October 3, 2025 (company announcement).
- A board meeting is scheduled for August 13, 2025, to consider unaudited financial results, the AGM date, reappointments of key executives, and a proposal for issuing bonus shares (company announcement).
- Alveolus Bio has closed a strategic financing round led by Shilpa Medicare. Shilpa Biologics will serve as the exclusive global development and manufacturing partner, accelerating clinical trials for next-generation inhaled therapies (company announcement).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at ₹514.5.
- Discount Rate holds steady at 12.73%.
- Revenue Growth forecast is unchanged at approximately 23.53%.
- Net Profit Margin projection remains stable at 25.39%.
- Future P/E ratio shows no material change and stays at 22.71x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.